Price T Rowe Associates Inc Prelude Therapeutics Inc Transaction History

Price T Rowe Associates Inc

$869 Billion
Q3 2024

A detailed history of Price T Rowe Associates Inc transactions in Prelude Therapeutics Inc stock. As of the latest transaction made, Price T Rowe Associates Inc holds 1,097,599 shares of PRLD stock, worth $1.47 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,097,599

Previous 891,298 23.15%

Holding current value

$1.47 Million

Previous $3.4 Million 33.09%

% of portfolio

0.0%

Previous 0.0%

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$2.07 - $6.37 $427,043 - $1.31 Million	206,301 Added 23.15%	1,097,599 $2.27 Million
Q2 2024 Aug 14, 2024	SELL	$3.32 - $5.63 $168,234 - $285,288	-50,673 Reduced 5.38%	891,298 $3.4 Million
Q1 2024 May 15, 2024	SELL	$2.68 - $4.84 $270,052 - $487,707	-100,766 Reduced 9.66%	941,971 $4.47 Million
Q4 2023 Feb 14, 2024	SELL	$1.69 - $4.37 $40,764 - $105,408	-24,121 Reduced 2.26%	1,042,737 $4.45 Million
Q3 2023 Nov 14, 2023	SELL	$2.74 - $4.79 $42,168 - $73,718	-15,390 Reduced 1.42%	1,066,858 $3.3 Million
Q2 2023 Aug 14, 2023	BUY	$4.45 - $8.12 $3.55 Million - $6.48 Million	797,886 Added 280.59%	1,082,248 $4.87 Million
Q1 2023 May 15, 2023	SELL	$4.58 - $7.34 $74,722 - $119,752	-16,315 Reduced 5.43%	284,362 $1.62 Million
Q4 2022 Feb 14, 2023	SELL	$4.61 - $8.5 $57,569 - $106,148	-12,488 Reduced 3.99%	300,677 $1.82 Million
Q3 2022 Nov 14, 2022	BUY	$5.0 - $8.82 $29,060 - $51,261	5,812 Added 1.89%	313,165 $2.07 Million
Q2 2022 Aug 15, 2022	SELL	$4.0 - $7.55 $62,540 - $118,044	-15,635 Reduced 4.84%	307,353 $1.6 Million
Q1 2022 May 16, 2022	BUY	$6.9 - $13.22 $128,726 - $246,632	18,656 Added 6.13%	322,988 $2.23 Million
Q4 2021 Feb 14, 2022	SELL	$11.89 - $31.74 $1.08 Million - $2.89 Million	-90,944 Reduced 23.01%	304,332 $3.79 Million
Q3 2021 Nov 15, 2021	SELL	$25.78 - $38.65 $142,460 - $213,579	-5,526 Reduced 1.38%	395,276 $12.4 Million
Q2 2021 Aug 16, 2021	SELL	$28.63 - $44.3 $635,271 - $982,972	-22,189 Reduced 5.25%	400,802 $11.5 Million
Q1 2021 May 17, 2021	BUY	$39.27 - $91.68 $1.39 Million - $3.24 Million	35,311 Added 9.11%	422,991 $18.3 Million
Q4 2020 Feb 16, 2021	BUY	$28.81 - $88.94 $11.2 Million - $34.5 Million	387,680 New	387,680 $27.7 Million

Others Institutions Holding PRLD

# of Institutions

Shares Held

35.7M

Call Options Held

500

Put Options Held

300

View Full List

About Prelude Therapeutics Inc

Ticker PRLD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,369,200
Market Cap $48.7M
Description
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid ...

More about PRLD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.

Account

Price T Rowe Associates Inc Prelude Therapeutics Inc Transaction History